Status:
COMPLETED
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
Lead Sponsor:
Rennes University Hospital
Conditions:
Renal Insufficiency, Chronic
Organ Graft
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In chronic kidney disease, ESAs (Erythropoiesis-stimulating agents) are used to treat anemia. This anemia is due to decreased renal production of erythropoietin (EPO), a hormone that stimulates the pr...
Detailed Description
Erythropoiesis-stimulating agents (ESAs) are numerous and prescribed, depending on the molecule, once a week to once a month. They have improved the management of pre-dialysis patients, increased thei...
Eligibility Criteria
Inclusion
- Patients monitored for chronic renal failure, or for renal transplantation regardless of clearance level;
- Patients whose disease requires regular injections of ESA (before hospitalization or since hospitalization);
- Patients who did not realize their injection themselves before hospitalization;
- Patients hospitalized in the nephrology department at Rennes university hospital ;
- Obtaining free, informed and written consent;
- Affiliation to social security.
Exclusion
- Major incapable persons and persons deprived of their liberty;
- Dialysis patients or for whom dialysis is envisaged within 3 months;
- Pregnant or nursing mothers;
- Patients who are already performing their ASE injections alone;
- Simultaneous participation in another research protocol involving the human person.
Key Trial Info
Start Date :
September 21 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2022
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03481686
Start Date
September 21 2018
End Date
February 9 2022
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Rennes
Rennes, France, 35000